Connecting clinical care, data and research
PartnershipsContact
← Back to publications

RESEARCH PUBLICATION / 2025

Original Article

Risk of new uveitis with JAK versus TNF inhibitors in ankylosing spondylitis and psoriasis

Comparative risk of uveitis with Janus kinase inhibitors versus tumor necrosis factor inhibitors in ankylosing spondylitis and psoriatic diseases: a target trial emulation study.

Frontiers in immunology

Citation & Authors

Front Immunol. 2025;16:1673970.

Wei-Hsuan Bai; Pei-Lun Liao; Yi-Chiao Bai; James Cheng-Chung Wei

ABSTRACT · CHINESE TRANSLATION

Translated abstract

Translated from the licensed abstract via the Chinese version. This is not an official journal translation.

purpose

To compare incident uveitis risk in patients with axial spondyloarthritis initiating JAK versus TNF inhibitors.

method

A target trial was emulated using real-world electronic health records from the TriNetX US Collaborative Network. Adults with ankylosing spondylitis (AS), psoriasis (PsO), or psoriatic arthritis (PsA) who newly initiated JAK or TNF inhibitors between January 1, 2016, and December 31, 2023, were identified. Groups were defined by initial treatment; 1:1 propensity score matching balanced demographics, comorbidities, prior medications, and laboratory values. With TNF inhibitors as the reference, Cox models estimated HRs and 95% confidence intervals for incident uveitis, and Kaplan–Meier analyses compared 9-year cumulative incidence. The primary outcome was incident uveitis after treatment initiation, with up to 9 years of follow-up.

result

From 697,850 patients, matching yielded 5,874 patients per group. JAK inhibitors were associated with a lower risk of incident uveitis than TNF inhibitors (HR 0.630; 95% CI 0.418–0.948), with consistent results after further adjustment for comorbidities, medications, and laboratory values. The protective association was consistent in patients aged ≥51 years (0.43; 0.24–0.79), White patients (0.59; 0.38–0.93), those with CRP ≥3 mg/L (0.50; 0.26–0.96), and those with ESR ≥20 mm/h (0.41; 0.19–0.87). Lower risk was observed both with and without concomitant conventional synthetic disease-modifying antirheumatic drugs: HR 0.50 (0.28–0.92) with concomitant use and 0.56 (0.33–0.94) without.

Conclusion

This large real-world cohort found that JAK inhibitors were associated with a significantly lower risk of incident uveitis than TNF inhibitors in patients with AS, PsO, or PsA, suggesting a potential role in mitigating ocular inflammation. Prospective studies and randomized controlled trials are needed to validate the findings and inform future clinical guidelines.

Original work: Author of the above paper. Source:Public Summary ↗. This translation is based on the Chinese rendering of the original English abstract.

Original work license:CC BY ↗;Translations are subject to the same licensing conditions.